Webinar Technology

New tools for exosome analysis: Applying imaging flow cytometry to cancer-derived exosomes

This webinar is brought to you by the Science/AAAS Custom Publishing Office

New tools for exosome analysis: Applying imaging flow cytometry to cancer-derived exosomes

28 March 2018

12:00 p.m. ET

Register now!


Exosomes, a type of small extracellular vesicle (EV) ranging in size from 30–200 nm in diameter, can be isolated from cell culture media as well as an array of biological fluids. There is considerable interest in analyzing the phenotypic characteristics of exosomes isolated from cancer patients in the hopes of developing helpful diagnostic tools. To date, exosomes have been analyzed by electron microscopy, Western blotting, and nanoparticle tracking. More recently, there has been an emerging interest in characterizing exosomes using imaging flow cytometry. In this webinar, viewers will see how imaging flow cytometry can be employed to study exosome internalization as well as the phenotypic characteristics of cancer patient–derived exosomes. The use of relevant controls will be discussed, including staining buffer controls, single color controls, exosome lysis by Triton X-100, and serial sample dilutions.

During this webinar, viewers will learn about:

  • Applying imaging flow cytometry to study exosome internalization
  • Using imaging flow cytometry to characterize cancer patient–derived exosomes
  • The benefits of imaging flow cytometry in preclinical and clinical studies.

Viewers can submit questions during the live broadcast!

This webinar will last for approximately 60 minutes.

This webinar is sponsored by MilliporeSigma. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

Speaker bios

Phillip Galbo Jr., B.S.

Albert Einstein College of Medicine
New York, NY

Mr. Galbo completed his undergraduate training at Niagara University, where he received a B.S. in biology. During his undergraduate years, he worked at the Roswell Park Cancer Institute (RPCI) Department of Flow and Image Cytometry, where he studied how to measure tumor-derived exosomes with conventional flow cytometry and imaging flow cytometry. Following graduation, Mr. Galbo continued his studies on tumor-derived exosomes in the Department of Neuro-Oncology at RPCI. In 2017, he accepted a research position at Dana-Farber Cancer Institute, where he studied molecular mechanisms that drive therapy resistance in aggressive prostate cancer. Currently, he is pursuing his Ph.D. at Albert Einstein College of Medicine, where he continues his focus on cancer biology.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here